FDA Approves Bristol Myers Squibb’s Zeposia (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis

FDA News, New FDA Approvals
May 27, 2021
A+ A-
Email Print

Article Link: FDA Approves Bristol Myers Squibb’s Zeposia (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis

PRINCETON, N.J.–(BUSINESS WIRE) May 27, 2021 — Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Zeposia (ozanimod) 0.92 mg for the treatment of adults with moderately to severely active…

Source: FDA New Drug Approvals

Newer Post
Older Post